Stifel analyst Paul Matteis raised the price target on Xenon Pharmaceuticals (NASDAQ: XENE) to $44.00 (from $31.00) while maintaining a ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

Xenon Pharmaceuticals (XENE) Prices 8.47M Share Offering at $29.50/shOctober 6, 2021 5:44 AM Xenon Pharmaceuticals (XENE) Files Mixed Shelf Registration StatementOctober 4, 2021 4:05 PM Xenon Pharmaceuticals (XENE) PT Raised to $50 at JefferiesOctober 4, 2021 11:23 AM Pre-Open Stock Movers 10/04: (XENE) (ADVM) (OSUR) Higher; (MRNA) (NEO) (IIVI) Lower (more...)October 4, 2021 9:25 AM Xenon's (XENE) X-Tole Data as Good as it Gets with Best-in-Category Efficacy - AnalystOctober 4, 2021 8:56 AM Form 8-K Xenon Pharmaceuticals For: Oct 04October 4, 2021 7:04 AM Xenon Pharmaceuticals (XENE) Phase 2b 'X-TOLE' Clinical Trial of XEN1101 for the Treatment of Focal Epilepsy Met its Primary Efficacy EndpointOctober 4, 2021 7:01 AM Xenon Pharmaceuticals Announces Positive Topline Results from Phase 2b ‘X-TOLE’ Clinical Trial of XEN1101 for the Treatment of Focal EpilepsyOctober 4, 2021 7:00 AM